Literature DB >> 21872334

Does colocated care improve access to cardiometabolic screening for patients with serious mental illness?

Amy M Kilbourne1, Zongshan Lai, Nicholas Bowersox, Paul Pirraglia, Mark S Bauer.   

Abstract

OBJECTIVE: Individuals with serious mental illness (SMI; e.g., schizophrenia, bipolar disorder) experience disparities in mortality relative to the general population, mainly because of medical conditions (i.e., cardiometabolic disease).We assessed whether VA patients with SMI and receiving care from VA mental health facilities with colocated medical care were more likely to receive cardiometabolic risk assessments in accordance with clinical practice guidelines than patients from noncolocated facilities.
METHODS: Patients with SMI identified prescribed second-generation antipsychotic medications in fiscal year (FY) 2007 receiving care from VA mental health facilities completing the VA Mental Health Program Survey were included. VA administrative data were ascertained to assess receipt of the following tests every 6 months in FY 2007: body mass index (BMI), blood pressure, lipid profile and fasting glucose.
RESULTS: Out of 40,600 patients with SMI prescribed second-generation antipsychotics, 29% received all cardiometabolic tests (lipid, glucose, BMI and blood pressure). While 79% and 76% received blood pressure and BMI assessments, respectively, only 37% received a lipid test. Patients from colocated sites were more likely to receive all cardiometabolic tests (odds ratio=1.26, 95% confidence interval: 1.18-1.35, P<.001).
CONCLUSIONS: Colocated general medical providers in mental health clinics are more likely to provide cardiometabolic assessments for patients with SMI prescribed second-generation antipsychotics. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21872334      PMCID: PMC3208760          DOI: 10.1016/j.genhosppsych.2011.07.003

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  16 in total

Review 1.  Consensus development conference on antipsychotic drugs and obesity and diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

2.  Characteristics of primary care visits for individuals with severe mental illness in a national sample.

Authors:  Gail L Daumit; Laura A Pratt; Rosa M Crum; Neil R Powe; Daniel E Ford
Journal:  Gen Hosp Psychiatry       Date:  2002 Nov-Dec       Impact factor: 3.238

3.  Medical risk in patients with bipolar disorder and schizophrenia.

Authors:  John W Newcomer
Journal:  J Clin Psychiatry       Date:  2006-11       Impact factor: 4.384

4.  A new kind of homelessness for individuals with serious mental illness? The need for a "mental health home".

Authors:  Thomas E Smith; Lloyd I Sederer
Journal:  Psychiatr Serv       Date:  2009-04       Impact factor: 3.084

5.  The global burden of disease, 1990-2020.

Authors:  A D Lopez; C C Murray
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

6.  From silos to bridges: meeting the general health care needs of adults with severe mental illnesses.

Authors:  Marcela Horvitz-Lennon; Amy M Kilbourne; Harold Alan Pincus
Journal:  Health Aff (Millwood)       Date:  2006 May-Jun       Impact factor: 6.301

7.  Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.

Authors:  Karen E Moeller; Sally K Rigler; Angela Mayorga; Niaman Nazir; Theresa I Shireman
Journal:  Schizophr Res       Date:  2010-12-18       Impact factor: 4.939

8.  Integrated medical care for patients with serious psychiatric illness: a randomized trial.

Authors:  B G Druss; R M Rohrbaugh; C M Levinson; R A Rosenheck
Journal:  Arch Gen Psychiatry       Date:  2001-09

9.  Medical comorbidity in women and men with schizophrenia: a population-based controlled study.

Authors:  Caroline P Carney; Laura Jones; Robert F Woolson
Journal:  J Gen Intern Med       Date:  2006-11       Impact factor: 5.128

10.  Quality of care for cardiovascular disease-related conditions in patients with and without mental disorders.

Authors:  Amy M Kilbourne; Deborah Welsh; John F McCarthy; Edward P Post; Frederic C Blow
Journal:  J Gen Intern Med       Date:  2008-07-15       Impact factor: 5.128

View more
  7 in total

1.  Evaluating the Impact of Integrated Care on Service Utilization in Serious Mental Illness.

Authors:  Heidi C Waters; Michael F Furukawa; Shari L Jorissen
Journal:  Community Ment Health J       Date:  2018-06-14

Review 2.  Serious mental illness and the role of primary care.

Authors:  Claire Planner; Linda Gask; Siobhan Reilly
Journal:  Curr Psychiatry Rep       Date:  2014-08       Impact factor: 5.285

3.  Community Mental Health Center Integrated Care Outcomes.

Authors:  Rebecca Wells; Bobbie Kite; Ellen Breckenridge; Tenaya Sunbury
Journal:  Psychiatr Q       Date:  2018-12

Review 4.  Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.

Authors:  Emma E McGinty; Julia Baller; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit
Journal:  Schizophr Bull       Date:  2015-07-28       Impact factor: 9.306

5.  Systematic Review of the Impact of Behavioral Health Homes on Cardiometabolic Risk Factors for Adults With Serious Mental Illness.

Authors:  Karen L Fortuna; Peter R DiMilia; Matthew C Lohman; Brandi P Cotton; Janet R Cummings; Stephen J Bartels; John A Batsis; Sarah I Pratt
Journal:  Psychiatr Serv       Date:  2019-09-10       Impact factor: 3.084

Review 6.  Excess mortality in bipolar disorders.

Authors:  Christopher Miller; Mark S Bauer
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

Review 7.  Screening for cardiovascular risk factors in adults with serious mental illness: a review of the evidence.

Authors:  Julia B Baller; Emma E McGinty; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit
Journal:  BMC Psychiatry       Date:  2015-03-21       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.